Xinhe Bio's Jointly Applied mRNA Key Technology Platform Project Receives National Key R&D Program Approval Under China's 14th Five-Year Plan

Jan 10, 2024 07:26 CST Updated 07:26

NeoCura

RNA Innovative Drug Developer

Recently, NeoCura jointly applied for"Establishment of a General Key Technology Platform for mRNA and Innovative Drug Development" Project Approved for the 2023 National Key Research and Development Program's "Frontier Biotechnology" Key Special Project.Becoming one of the "application demonstration" tasks that is a key national priority.

This project brings togetherWisgen Biotechnology, NeoCura, Sichuan University, Zhejiang University, National Center for Nanoscience and Technology, National Institutes for Food and Drug ControlTeams of "industry-academia-research-medicine-inspection" collaborate on key technology breakthroughs for mRNA drugs, accelerating foundational research such as AI-powered construction of mRNA sequences and delivery systems, large-scale production of mRNA bulk solutions and finished products, and safety evaluations of mRNA drugs. They continuously improve the in vivo delivery and expression efficiency of mRNA drugs, strengthen the foundation of mRNA technology, and lead a leapfrog development of mRNA technology in China.

National Key R&D Program projects are the main channel for supporting major scientific and technological breakthroughs in China. To implement the deployment arrangements for national scientific and technological innovation during the "14th Five-Year Plan" period, the National Key R&D Program has launched the "Frontier Biotechnology" key special project. Its overall goal is to achieve breakthroughs in a number of disruptive frontier biotechnologies, enhance China's original innovation capabilities in life sciences and frontier biotechnology, construct the basic framework of a biotechnology system, provide new impetus for guiding, supporting, and innovatively developing China’s biotechnology industry, lead the biotechnology industrial revolution, and make it a strong support for high-quality development in fields such as health and manufacturing.

The project " Establishment of a General Key Technology Platform for mRNA and Innovative Drug Development" has been approved for establishment. This not only demonstrates the determination of the country to promote the industrialization of China's original mRNA drugs with a global perspective by coordinating resources and elements, but also highlights the importance placed by the country on innovation and breakthroughs in key mRNA technologies. This project brings together leading organizations in the mRNA field in China and forms a high-level R&D team in the interdisciplinary areas of industry, academia, research, medicine, and testing, assisting China in developing innovative mRNA drugs with independent intellectual property rights that are safe and efficient.

In 2023, mRNA technology won the Nobel Prize in Physiology or Medicine, further unleashing its application potential. As a pioneer in China’s mRNA field, NeoCura has consistently adhered to an innovation model driven by technology. It has independently developed a technology platform covering the entire R&D process, empowered by algorithms for target discovery, sequence optimization, and drug delivery, providing solid technical support for mRNA innovative drug research and development. Meanwhile, NeoCura continues to expand and revolutionize its technology platform, promoting better targeting, efficacy, and safety of mRNA innovative drugs.

In the future, NeoCura will continue to align with national strategic needs, taking it as its mission to solve key technical challenges in the mRNA industry. It will strengthen scientific and technological innovation and research efforts, deepen the "industry-university-research-medical-inspection" collaborative innovation system, continuously enhance technical capabilities and innovation, and contribute to the construction of "Healthy China."